Anton Wohl, MD

CURRENT POSITION

Neurosurgeon, Neurosurgical Oncology & Stereotactic Radiosurgery Service, 
             Department of Neurosurgery, Sheba Medical Center Tel Hashomer, Israel

I am an Israeli Board and Russian Board certified neurosurgeon with extensive experience in the fields of general and oncological neurosurgery, including malignant and benign brain tumor surgery, intraoperative MRI assisted surgery, awake brain surgery and intraoperative brain mapping, brain biopsy, stereotactic radiosurgery. Additionally, I gained extensive experience in a wide range of neurosurgical procedures throughout neuro-trauma, functional and aesthetic correction of post-traumatic or post-operative skull defects and treatment of hydrocephalus. 

One of the major part of my practice is seeking to develop and rigorously test techniques facilitating aggressive surgical resection for gliomas while maintaining or improving patient safety. These include integrating functional imaging (functional MRI) into image-guidance navigation systems and intra-operative MRI and US, correlating this with intra-operative electrophysiological mapping, and pursuing novel strategies such as fluorescence-guided resection.

 My research activity focused on Clinical and Basic Science Research in the treatment of malignant brain tumors.  

EDUCATION

FELLOWSHIP
2018-2020    Stereotactic Radiosurgery, Department of Neurosurgery, 
             Sheba Medical Center Tel Hashomer, Israel    
             Mentor:  Spiegelmann Roberto, MD

2016-2017    Oncological Neurosurgery, Department of Neurologic Surgery, 
             Mayo Clinic, Rochester, MN, USA                                                                                                                      
          Mentors:  Fredric B Meyer, MD, David J Daniels, MD, PhD 
          

RESIDENCY

2009-2015     Neurosurgery, Sheba Medical Center Tel Hashomer, Israel

MD
1996-2002     Ural State Medical Academy, Yekaterinburg, Russia, Diploma cum laude 

EMPLOYMENT 

2008-2015.  tel hashomer, department of neurosurgery, neiurosurgeon, residency 

2016-2017  mayo clinic, department of neurologic surgery, neurosurgeon, felowship

2017-now. tel hashomer, department of neurosurgery, consulting neurosurgeon
 

POSTGRADUATE EDUCATION AND BOARD CERTIFICATIONS

    2002-2003  Internship in Neurology , Ural State Medical Academy, Yekaterinburg, Russia
    2003       General Neurosurgery, Institute of Neurosurgery’ Burdenko, Moscow, Russia
    2006       Diagnostic Radiology, Ural State Medical Academy, Yekaterinburg, Russia
    2008       Israeli Medical License 
    2011       GCP: Design, Conduct & Management of Clinical Trials, Israel
    2012       ATLS / Military Trauma Life Support, Tsrifin, Israel 
    2012       AO SPINE - Trauma and Degenerative Spine Workshop, Tel Aviv, Israel
    2013       EANS, AANS/CNS: International Neuro-Oncology Updates, Tel Aviv, Israel 
    2014       Israeli Neurosurgery Board Certification 
    2016       Microvascular Surgery Training Course, Mayo Clinic, Rochester, MN, USA
    2021       ACLS, Tel Hashomer, Israel (2009, 2014, 2017, 2019, 2021)
    2021       Brain and Spinal Radiosurgery, Brainlab Training Center, Munich, Germany 

BASIC SCIENCE RESEARCH

Human cytomegalovirus in malignant brain gliomas (pub.), Israel, Sheba Medical Center, 2010.
Effects of peripheral blood-derived γ9δ2 T-cells from patients with GBM (pub.), Israel, Sheba Medical Center, 2013.
Targeting of GBM by the loaded nanoparticles (pub.) Israel, Sheba Medical Center, 2014. 
Expression of Klotho protein in GBM. (pub.) Israel, Sheba Medical Center, collaboration with Tel Aviv Medical Center, 2013.
Treatment strategy of GBM with PAR1- inhibitor. (pub.) Israel, Sheba Medical Center, 2015-2016. 
Effects of Apixaban in ischemic stroke in mice model. (pub.) Israel, Sheba Medical Center, 2016. 
Developing of animal model of DIPG H3K27 mutant tumor and its treatment strategies. (pub.) Mayo Clinic, Rochester, MN, US, 2016-2017.
Epigenetic screening of small experimental molecules and treatment of various DIPG cell lines in vitro. Mayo Clinic, Rochester, MN, US, 2016-2017.
Opening of Brain-Blood Barrier by the means of Focus Ultra Sound Technic in animal model. Israel, Sheba Medical Center collaboration with Insightec. 2019-2020. (pub.)  
Alpha Particles modulated intratumoral Radiation Therapy of recurrent High Grade Gliomas. Israel, Sheba Medical Center & Alpha TAU Company. Medical device development. Co-investigator. 2020-now.
Targeting therapy of Medulloblastoma (mice model). Israel, Sheba Medical Center, 2020- now.  
 

CLINICAL RESEARCH

• SAPPHIRE international clinical trial. Efficacy and Safety of AP12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) as Compared to Standard Treatment with Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study, 2010-2012. 
• CLEAR III Trial. A phase III randomized clinical trial using rtPA to treat subjects with intraventricular hemorrhage. Co-investigator. 2010- 2014.
• nICP monitoring. A continuous, real-time, non-Invasive Intracranial Pressure monitoring device. Medical device development. Collaboration of Sheba Medical Center and Orsan Medical Technologies. Co-investigator. 2011-2014.
• SyNAPSe Trial. A phase III study of the neuroprotective activity of progesterone in severe traumatic brain injuries. Co-investigator. 2011-2013.
• Oxycyte Trial. A Phase II, dose escalation, clinical trial for use of Oxycyte as an emergency treatment for traumatic brain injury. Oxycyte is a third-generation perfluorocarbon designed to enhance oxygen delivery to damaged. Co-investigator. 2010- 2013. 
• Noninvasive pupil response for focal chromatic light stimuli in patients with intracranial lesion. Israel, Sheba Medical Center. Medical device development. Co-investigator. 2017-2020.

PUBLICATIONS

1.    Human cytomegalovirus viral load in tumor and peripheral blood samples of                           patients with malignant gliomas. 
Priel E, Wohl A, Teperberg M, Nass D, Cohen ZR. 
Journal of Clinical Neuroscience. 2015 Feb; 22(2):326-30. 

2.    Localized RNAi Therapeutics of Chemo-Resistant Grade IV Glioma using   Hyaluronic-Grafted Lipid-based Nanoparticles. 
Cohen ZR, Ramisetty S, Peshes –Yaloz N, Goldsmith M, Wohl A, Zibly Z, Peer D. 
American Chemical Society. Nano. 2015 Feb 24; 9(2):1581-91. 

3.    Peripheral blood-derived, γ9δ2 t cell-enriched cell lines from glioblastoma multiforme patients exert anti-tumoral effects in vitro. 
Marcu-Malina V, Garelick D, Peshes-Yeloz N, Wohl A, Zach L, Nagar M, Amariglio N, Besser MJ, Cohen ZR, Bank I. 
Journal of Biological Regulators and Homeostatic Agents. 2016 Jan-Mar; 30(1):17-30.
 
4.    Predicting and reducing cranioplasty infections by clinical, radiographic and operative parameters - A historical cohort study. 
Kimchi G, Stlylianou P, Wohl A, Hadani M, Cohen ZR, Zauberman J, Feldman Z, Spiegelmann R, Nissim O, Zibly Z, Penn M, Harnof S. 
Journal of Clinical Neuroscience. 2016 Jul 16. pii: S0967-5868(16)30321-6. 

5.    A novel swine model of subarachnoid hemorrhage-induced cerebral vasospasm.
Zibly Z, Fein L, Sharma M, Assaf Y, Wohl A, Harnof S. 
Neurology India. 2017 Sep-Oct; 65(5):1035-1042. doi: 10.4103/neuroindia.NI_357_16.

6.    Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke.
Bushi D, Chapman J, Wohl A, Stein ES, Feingold E, Tanne D. 
Journal of Neuroscience Research. 2018 Aug; 96(8):1406-1411. doi: 10.1002/jnr.24253. Epub 2018 May 14.

7.    Novel suprasellar location of desmoplastic infantile astrocytoma and ganglioglioma: a single institution's experience.
Naylor RM, Wohl A, Raghunathan A, Eckel LJ, Keating GF, Daniels DJ.
Journal of Neurosurgery. Pediatrics. 2018 Jul 6:1-7. doi: 10.3171/2018.4. PEDS17638.

8.    A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma.
Shavit-Stein E, Sheinberg E, Golderman V, Sharabi S, Wohl A, Gofrit SG, Zivli Z, Shelestovich N, Last D, Guez D, Daniels D, Gera O, Feingold K, Itsekson-Hayosh Z, Rosenberg N, Tamarin I, Dori A, Maggio N, Mardor Y, Chapman J, Harnof S.
Frontiers in Neurology. 2018 Dec 17;9:1087. doi: 10.3389/fneur.2018.01087. eCollection 2018.

9.    Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
Welby JP, Kaptzan T, Wohl A, Peterson TE, Raghunathan A, Brown DA, Gupta SK, Zhang L, Daniels DJ.
Frontiers in Oncology. 2019 Feb 27; 9:92. doi: 10.3389/fonc.2019.00092. eCollection 2019.

10.    Role of Klotho Protein in Tumor Genesis, Cancer Progression, and Prognosis in Patients with High-Grade Glioma.
Peshes-Yeloz N, Ungar L, Wohl A, Jacoby E, Fisher T, Leitner M, Nass D, Rubinek T, Wolf I, Cohen ZR. 
World Neurosurgery. 2019 Jun 20 pii: S1878-8750(19) 31634-1. doi: 10.1016/j.wneu. 2019.06.082.

11.    Brain Metastases from Ovarian Carcinoma: An Evaluation of Prognostic Factors and Treatment.
Wohl A, Kimchi G, Korach J, Perri T, Zach L, Zibly Z, Harel R, Nissim U, Spiegelmann R, Nass D, Cohen ZR.
Neurology India. 2019 Nov-Dec;67(6):1431-1436. doi: 10.4103/0028-3886.273627.
    PMID: 31857529

12.    Early Fluid Attenuation Inversion Recovery Sulcal Contrast Enhancement Correlates with Severity of Reversible Cerebral Vasoconstriction Syndrome. 
Itsekson-Hayosh Z, Tsarfati G, Greenberg G, Sharon M, Bakon M, Wohl A, Chapman J, Orion D. 
Journal of Stroke. 2020 Sep;22(3):400-402. doi: 10.5853/jos.2020.01004. Epub 2020 Sep 29. PMID: 33053955

13.    Utility of the Polestar N30 low-field MRI system for resecting non-enhancing intra-axial brain lesions. 
Ungar L, Zibly Z, Wohl A, Harel R, Hadani M, Attia M, Spiegelmann R, Feldman Z, Zaubermann J, Knoller N, Cohen ZR.
Neurologia i Neurochirurgia Polska. 2021 Feb 9. doi: 10.5603/PJNNS.a2021.0017.
    PMID: 33559873

14.    Comparison of Frame-Based Versus Frameless Image-Guided Intracranial Stereotactic Brain Biopsy: A Retrospective Analysis of Safety and Efficacy. 
Ungar L, Nachum O, Zibly Z, Wohl A, Harel R, Attia M, Spiegelmann R, Zaubermann J, Feldman Z, Knoller N, Cohen ZR. 
World Neurosurgery. 2021 Jul 28:S1878-8750(21)01070-6. doi: 10.1016/j.wneu.2021.07.063. PMID: 34332151

15.     Magnetic resonance imaging analysis predicts nanoparticle concentration delivered to the brain parenchyma.
Plaksin M, Bercovici T, Sat Toltsis GG, Grinfeld J, Shapira B, Zur Y, de Picciotto R, Zadicario E, Siddeeq M, Wohl A, Zibly Z, Levy Y, Cohen ZR.
Communication Biology - Nature. 2022 Sep 15;5(1):964. doi: 10.1038/s42003-022-03881-0.
PMID: 36109574 

                                             
ORAL PRESENTATIONS 
Cranial defects reconstructed with cranioplasty implants produced using three-dimensional printing. 
Wohl A, Penn M, Hadani M, Harnof S. 
Annual meeting of the Israeli neurosurgical society. Jerusalem, Israel, 18-19th, March, 2010

PROFESSIONAL ACTIVITIES

    2013 - Instructor, Anatomy of Central Neural System, Tel Aviv University, Israel
    2017 - Current   Lecturer, Neurosurgery, Tel Aviv University, Israel